A novel clinical trial that uses artificial intelligence to rapidly compare Covid-19 treatments has attracted participation from two major drug companies, a key milestone in the effort to shake up the way trials are conducted.
Amgen and the Japanese pharmaceutical company Eisai will become the first pharma companies to test their experimental therapies in REMAP-CAP, an adaptive clinical trial that seeks to rapidly evaluate potential Covid-19 treatments in patients around the world.
It relies on a type of artificial intelligence known as reinforcement learning to adjust treatment protocols based on how different therapies affect patient outcomes, like a chef tweaking a recipe based on feedback from each wave of diners.
About the Author Reprints
